Insider Transactions in Q4 2023 at Apellis Pharmaceuticals, Inc. (APLS)
Insider Transaction List (Q4 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 27
2023
|
Jeffrey Eisele Chief Development Officer |
SELL
Open market or private sale
|
Direct |
235
-0.44%
|
$14,100
$60.23 P/Share
|
|
Dec 26
2023
|
Jeffrey Eisele Chief Development Officer |
SELL
Open market or private sale
|
Direct |
68
-0.13%
|
$3,876
$57.86 P/Share
|
|
Dec 19
2023
|
David O. Watson General Counsel |
SELL
Open market or private sale
|
Direct |
3,905
-2.11%
|
$222,585
$57.19 P/Share
|
|
Dec 19
2023
|
David O. Watson General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
7,905
+7.78%
|
$102,765
$13.85 P/Share
|
|
Dec 14
2023
|
A. Sinclair Dunlop Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,274
+4.65%
|
$81,562
$13.19 P/Share
|
|
Dec 01
2023
|
Lukas Scheibler Chief Research Officer |
SELL
Open market or private sale
|
Direct |
10,000
-12.77%
|
$600,000
$60.0 P/Share
|
|
Dec 01
2023
|
Lukas Scheibler Chief Research Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+11.33%
|
$130,000
$13.85 P/Share
|
|
Dec 01
2023
|
Adam J. Townsend Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
110,000
-35.98%
|
$6,600,000
$60.91 P/Share
|
|
Dec 01
2023
|
Adam J. Townsend Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
110,000
+37.11%
|
$1,650,000
$15.09 P/Share
|
|
Dec 01
2023
|
A. Sinclair Dunlop Director |
SELL
Open market or private sale
|
Indirect |
24,000
-11.08%
|
$1,464,000
$61.13 P/Share
|
|
Nov 30
2023
|
Timothy Eugene Sullivan Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
14,158
-7.73%
|
$764,532
$54.76 P/Share
|
|
Nov 30
2023
|
Timothy Eugene Sullivan Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,158
+13.35%
|
$141,580
$10.03 P/Share
|
|
Nov 21
2023
|
Cedric Francois Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,000
-1.82%
|
$240,000
$48.8 P/Share
|
|
Nov 17
2023
|
A. Sinclair Dunlop Director |
SELL
Open market or private sale
|
Direct |
8,894
-6.77%
|
$435,806
$49.99 P/Share
|
|
Nov 17
2023
|
Alec Machiels Director |
SELL
Open market or private sale
|
Direct |
1,250
-0.34%
|
$58,750
$47.74 P/Share
|
|
Nov 17
2023
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+0.34%
|
$2,500
$2.67 P/Share
|
|
Nov 14
2023
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
45,000
+3.87%
|
$135,000
$3.76 P/Share
|
|
Nov 08
2023
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
12,000
-1.11%
|
$564,000
$47.27 P/Share
|
|
Nov 08
2023
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,494
+1.59%
|
$34,988
$2.67 P/Share
|
|
Oct 23
2023
|
James George Chopas VP/Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
132
-0.4%
|
$6,072
$46.04 P/Share
|
|
Oct 23
2023
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Open market or private sale
|
Direct |
131
-0.25%
|
$6,026
$46.04 P/Share
|
|
Oct 17
2023
|
A. Sinclair Dunlop Director |
SELL
Open market or private sale
|
Indirect |
24,000
-9.97%
|
$1,176,000
$49.0 P/Share
|
|
Oct 17
2023
|
Alec Machiels Director |
SELL
Open market or private sale
|
Direct |
1,250
-0.34%
|
$60,000
$48.5 P/Share
|
|
Oct 17
2023
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+0.34%
|
$2,500
$2.67 P/Share
|
|
Oct 09
2023
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
12,000
-1.11%
|
$480,000
$40.38 P/Share
|
|
Oct 09
2023
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,500
+1.69%
|
$37,000
$2.67 P/Share
|